What is UroGen Pharma's restricted cash?

UroGen Pharma (URGN) reported restricted cash of $1.33M in Q1 2026.

How has UroGen Pharma's restricted cash changed year-over-year?

UroGen Pharma's restricted cash increased by 23.3% year-over-year, from $1.08M to $1.33M.

What is the long-term trend for UroGen Pharma's restricted cash?

Over 5 years (2020 to 2025), UroGen Pharma's restricted cash has grown at a 1.9% compound annual growth rate (CAGR), from $1.23M to $1.35M.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

UroGen Pharma URGN Restricted Cash

Restricted Cash at other companies

Merck & Co.MRK

$71M-31.1%

Tyra Biosciences, Inc.TYRA

$884K-11.6%

ImmunomeIMNM

$210K+110%

LQD

Liquidia CorporationLQDA

$3.5M—

TG TherapeuticsTGTX

$1.35M+3.8%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's restricted cash?: UroGen Pharma (URGN) reported restricted cash of $1.33M in Q1 2026.
How has UroGen Pharma's restricted cash changed year-over-year?: UroGen Pharma's restricted cash increased by 23.3% year-over-year, from $1.08M to $1.33M.
What is the long-term trend for UroGen Pharma's restricted cash?: Over 5 years (2020 to 2025), UroGen Pharma's restricted cash has grown at a 1.9% compound annual growth rate (CAGR), from $1.23M to $1.35M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.